Manzo Pharmaceuticals announces successful results in laboratory tests of its lactose intolerance probiotic Lacto-Freedom

MILFORD, Pa., Sept. 29, 2014 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink:FOGCD), today announced at the three month mark in a six month animal study, that the results of the lactase producing probiotic, Lacto-Freedom™, has been very successful. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.  

The 6-month study is being conducted by Celprogen,Inc. using laboratory rats to test the new probiotic treatment. Lab rats are the ideal mammals to test because they are naturally lactose intolerant. After 3 months the rats given the treatment showed no negative side effects, even at very high doses.  All doses from low to high concentration were very successful at colonizing the intestines and producing lactase, which enabled rats to digest lactose.  This effect lasted for a full three months after the administration of the probiotic was discontinued.  This long lasting residual effect is unique and is far superior to any other lactose intolerance treatment option currently on the market. Since approximately 25% of the population in the United States is lactose intolerant Manzo Pharmaceuticals and Celprogen are both confident that there will be a huge demand for this product.

Jay Sharma, CEO of Celprogen, stated, "we are very pleased with the results so far and everyone is eager to see how long the effects last. Its possible that the effects could last six months or beyond, and because of that we would like to start looking for a company to do a small human clinical trial"

In addition to the tremendous progress with Lacto-Freedom™, Manzo Pharmaceutical CEO, Ken Manzo wants shareholders to know that although he has been occupied with the recent name change and corporate re-structuring he has been keeping shareholder value in mind, and recently filed for a reduction in authorized shares from 5 Billion to only 950 million because he wants to control and limit future dilution, therefore maintaining and growing shareholder value. It's clear that Manzo Pharmaceuticals is positioning itself to be a powerful player in the pharmaceutical industry.

DISCLAIMER

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

SOURCE Manzo Pharmaceuticals, Inc.